Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 29 | 37 | 44 | 47 | 53 | 59 | 61 | 63 |
| Operating profit | $bn | 14 | 14 | ||||||
| Net profit | $bn | 3 | 0 | 3 | 6 | 7 | 10 | 10 | 16 |
| EPS reported | $ | 6.54 | 6.68 | ||||||
| Operating cashflow per share | $ | 9.40 | 8.86 | ||||||
| Capex per share | $ | 3.81 | 3.42 | ||||||
| FCF per share | $ | 5.59 | 5.44 | ||||||
| Free cash flow | $bn | 9 | 8 | ||||||
| Net debt | $bn | 22 | 27 | ||||||
| Book value equity | $bn | 49 | 51 | ||||||
| Book value per share | $ | 31.16 | 32.41 | ||||||
| Number of shares | m | 1,562 | 1,560 | ||||||
| DPS (TTM paid) | $ | 3.18 | 3.22 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 28.37 | 23.69 | ||||||
| P/B LTM | x | 5.91 | 4.82 | ||||||
| P/S LTM | x | 4.90 | 3.98 | ||||||
| P/FCF LTM | x | 33.17 | 28.91 | ||||||
| EV/EBITDA LTM | x | 15.71 | 13.26 | ||||||
| EV/Sales LTM | x | 5.30 | 4.43 | ||||||
| Earnings Yield LTM | % | 3.52% | 4.22% | ||||||
| FCF Yield | % | 3.01% | 3.46% | ||||||
| Quality | |||||||||
| ROE | % | 21.01% | 21.68% | ||||||
| ROIC | % | 13.04% | 12.69% | ||||||
| Operating margin | % | 23.40% | 22.69% | ||||||
| Gross margin | % | 81.90% | 79.27% | ||||||
| FCF/Sales | % | 14.76% | 13.76% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +48.30% | +23.48% | ||||||
| Sales Growth YoY | % | +10.95% | +6.93% | ||||||
| Net Income Growth YoY | % | +48.44% | +23.49% | ||||||
| FCF Growth | % | +19.18% | +3.03% | ||||||
| Operating Profit Growth | % | +9.75% | +14.46% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.73% | 2.05% | ||||||
| Dividend Growth | % | +9.46% | +1.83% | ||||||
| Payout Ratio | % | 48.66% | 47.05% | ||||||
| FCF/Debt | x | 0.29 | 0.26 | ||||||
| Net Debt/EBITDA | x | 1.21 | 1.34 | ||||||
| EBIT/Net interest | x | 8.11 | 7.97 | ||||||
| Net debt/market cap | % | 7.68% | 11.25% | ||||||
| Net debt/Equity | x | 0.45 | 0.54 | ||||||
| Gross debt/equity | x | 0.61 | 0.64 | ||||||
ETFs that hold AstraZeneca
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Core MSCI EAFE ETF | IEFA | 7 | 0.99% |
| iShares MSCI EAFE ETF | EFA | 7 | 1.15% |
| Schwab International Equity ETF | SCHF | 10 | 0.82% |
| State Street SPDR Portfolio Developed World ex-US ETF | SPDW | 10 | 0.74% |
| Vanguard FTSE Europe ETF | VGK | 7 | 1.49% |
| iShares Core MSCI International Developed Markets ETF | IDEV | 8 | 0.87% |
| Amundi Core Stoxx Europe 600 UCITS ETF Acc | LYP6.DE | 6 | 1.68% |
| Dimensional - International Core Equity Market ETF | DFAI | 7 | 0.73% |
| iShares Core MSCI Europe UCITS ETF EUR (Acc) | EUNK.DE | 6 | 1.81% |
| iShares Core MSCI EAFE IMI Index ETF | XEF.TO | 8 | 0.97% |
Funds with AstraZeneca among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Core MSCI EAFE ETF | IEFA | 7 | 0.99% |
| iShares MSCI EAFE ETF | EFA | 7 | 1.15% |
| Schwab International Equity ETF | SCHF | 10 | 0.82% |
| State Street SPDR Portfolio Developed World ex-US ETF | SPDW | 10 | 0.74% |
| Vanguard FTSE Europe ETF | VGK | 7 | 1.49% |
| iShares Core MSCI International Developed Markets ETF | IDEV | 8 | 0.87% |
| Amundi Core Stoxx Europe 600 UCITS ETF Acc | LYP6.DE | 6 | 1.68% |
| Dimensional - International Core Equity Market ETF | DFAI | 7 | 0.73% |
| iShares Core MSCI Europe UCITS ETF EUR (Acc) | EUNK.DE | 6 | 1.81% |
| iShares Core MSCI EAFE IMI Index ETF | XEF.TO | 8 | 0.97% |
Funds with AstraZeneca among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free